Retatrutide vs Mazdutide: Mechanistic Receptor Comparison

Research Notice: Neither Retatrutide nor Mazdutide is FDA-approved for any use. Both are investigational compounds in active clinical development programmes. BehemothLabz supplies Retatrutide strictly for laboratory research only. This article is a mechanistic comparison of published investigational data only — not guidance for any non-research application.

Quick Answer

Key mechanistic difference: Retatrutide (LY3437943) is a triple agonist targeting GLP-1R, GIPR, and GCGR. Mazdutide (LY3502970) is a dual agonist targeting GLP-1R and GCGR only — without GIP receptor engagement. Both are in Phase 2–3 clinical development and are not approved for any use.

Researchers looking to buy Retatrutide for laboratory investigation can source it as a research-grade compound at BehemothLabz. All products are independently third-party tested, with COA available per batch. Sold strictly for laboratory research only.

Disclaimer: Retatrutide (LY3437943) is a research compound not approved by the U.S. FDA for any use. Strictly for laboratory research only.

Compound Overview

Retatrutide (LY3437943): A synthetic peptide triple agonist targeting GLP-1R (GLP-1 receptor), GIPR (GIP receptor), and GCGR (glucagon receptor). Developed by Eli Lilly. Phase 2 data published in NEJM 2023 (Jastreboff et al.) documented up to 24.2% mean weight loss at 48 weeks vs 2.1% placebo in an obesity trial. Phase 3 ongoing. Not FDA-approved.

Mazdutide (LY3502970): A dual agonist targeting GLP-1R and GCGR. Does not engage GIPR. Under clinical investigation, primarily in Asia (Phase 3 in China). Not FDA-approved in any jurisdiction at the time of this publication.

Receptor Mechanism Comparison

• GLP-1R agonism: Both compounds activate GLP-1R, producing appetite suppression, incretin-mediated insulin secretion enhancement, and gastric emptying delay in investigational data.
• GIPR agonism: Retatrutide: Yes — GIP receptor engagement adds incretin synergy and potential adipose tissue effects in investigational data. Mazdutide: No GIP receptor engagement.
• GCGR agonism: Both compounds activate the glucagon receptor, driving hepatic fat oxidation and energy expenditure enhancement in preclinical and investigational data.
• Triple vs dual agonism: Retatrutide's additional GIP receptor engagement is the primary mechanistic distinction. Published data suggest GIP agonism adds adipose-specific signalling beyond what GLP-1R alone achieves.
• Weight loss data: Retatrutide (Jastreboff et al. 2023): up to 24.2% at 48 weeks (Phase 2). Mazdutide: Phase 2/3 data from China-based trials; direct comparison not available in published English-language literature.

Risks and Limitations of Retatrutide Research

Mandatory reading before working with this compound in any laboratory setting.

Research-Only Framing

Retatrutide Nasal Spray is an investigational compound in active Phase 3 development. All information is from published investigational literature only. No dosage guidance or efficacy claims are applicable outside approved clinical trial settings.

Handling Precautions

Handle with trained laboratory personnel. Use appropriate PPE. Verify COA per batch.

Storage

Store per compound-specific stability data. Lyophilised peptides are typically stored at −20°C.

IACUC Compliance

All animal model research involving retatrutide must be conducted under IACUC-compliant protocols.

Data Limitations

Phase 3 data are not fully published. All weight loss and mechanistic data referenced are from Phase 2 investigational studies only. 

Conclusion

Retatrutide and Mazdutide are both GLP-1R/GCGR dual or triple agonists in clinical development. The key mechanistic distinction is GIPR engagement: retatrutide adds GIP receptor agonism to the GLP-1R/GCGR dual mechanism, which published investigational data associate with enhanced adipose signalling and weight loss outcomes. Neither compound is FDA-approved. BehemothLabz supplies retatrutide for laboratory research only.

Retatrutide is available for sale at BehemothLabz for licensed laboratory research use only. Each batch is independently third-party tested, and a Certificate of Analysis (COA) is available per batch. Not for any other use.

FAQs

What is the key mechanistic difference between retatrutide and mazdutide?

Retatrutide engages three receptors: GLP-1R, GIPR, and GCGR (triple agonist). Mazdutide engages two: GLP-1R and GCGR (dual agonist), without GIP receptor involvement. The GIP receptor engagement is the primary mechanistic distinction.

Are either of these FDA-approved?

No. Neither retatrutide nor mazdutide is FDA-approved. Both are investigational compounds in active clinical development.

Where can I buy Retatrutide for research?

BehemothLabz offers Retatrutide for sale for laboratory research purposes only. Each batch is independently third-party tested, with a COA available per batch.

ATTENTION — BehemothLabz Research Compound Notice

All BehemothLabz products are strictly for LABORATORY AND RESEARCH PURPOSES ONLY. Not for any other use. Contact support@behemothlabz.com with any concerns.

References

•       Jastreboff AM, Kaplan LM, Frías JP, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. New England Journal of Medicine. 2023;389(6):514–526. https://pubmed.ncbi.nlm.nih.gov/37366315/
•       Coskun T, Urva S, Roell WC, et al. LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: from discovery to clinical proof of concept. Cell Metabolism. 2022;34(9):1234–1247.e9. https://pubmed.ncbi.nlm.nih.gov/35931029/